China Construction Bank Corporation (601939.SS) vs AbbVie Inc. (ABBV)

China Construction Bank Corporation is one of China’s largest commercial banks, with a strong position in infrastructure finance, mortgages, corporate banking, deposits, payments, and wealth management. The bank serves households, government-linked entities, property developers, industrial companies, and small businesses. Its performance is shaped by Chinese loan demand, interest margins, deposit growth, asset quality, and public policy. Because of its scale, it is closely connected to China’s broader credit cycle and domestic economic conditions.

AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.